Are you a patient?

Dosing and titration guide

ENTRESTO can replace an ACEi or ARB.1

ENTRESTO is available in the following doses1:

Target dose is one 97 mg/103 mg tablet twice daily1

ENTRESTO must NOT be co-administered with an ACEi or an ARB.1


  • Hypersensitivity to the active substances, sacubitril and valsartan, or to any of the excipients
  • Concomitant use with an ACEi. ENTRESTO must not be administered until 2 days after discontinuing ACEi therapy (a 2-day washout period is suggested)*
  • Known history of angioedema related to previous ACEi or ARB therapy
  • Hereditary or idiopathic angioedema
  • Concomitant use with aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2)
  • Severe hepatic impairment, biliary cirrhosis and cholestasis
  • Second and third trimesters of pregnancy

Please refer to the Summary of Product Characteristics for full dosing information.

* Summary of Product Characteristics states a washout period of 36 hours.

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; eGFR = estimated glomerular filtration rate; HF = heart failure


  1. ENTRESTO Summary of Product Characteristics.

Date of preparation: March 2016 ENT16-C022f